We use first and third-party cookies to offer our services and collect statistical data. If you continue browsing this website you accept their use. More information Accept
INKE Neuraxpharm


HIGHEST QUALITY
ACTIVE PHARMACEUTICAL INGREDIENTS (APIs)
SINCE 1980

MORE
Respiratory inhalation

FOCUS ON RESPIRATORY

High-added-value active pharmaceutical ingredients for use in respiratory therapies such as:

· ARFORMOTEROL · FORMOTEROL 
· GLYCOPYRROLATE · INDACATEROL 
· SALMETEROL · TIOTROPIUM

MORE
EXPERTISE IN COMPLEX SYNTHESIS
Inke has been developing, patenting and implementing its own synthetic routes
and polymorphs to meet each customer's technical and regulatory needs
MORE
Respiratory APIs

15 RESPIRATORY APIs
FOR INHALATION

In continuous international expansion since 1998, Inke provides full support to its customers worldwide

8 EU CEPs GRANTED

9 CEPs

GRANTED

13 US DMFs filed

13 DMFs

FILED

 Japan 8 DMFs

8 DMFs

FILED

Korea 8 DMFs

6 DMFs

FILED

Canada 2 2 DMFs filed

4 DMFs

FILED

In-house micronisation

IN-HOUSE MICRONISATION

More than 20 years' experience in micronisation

We have built this capability in-house to ensure quality results from our customised products

MORE
Neuraxpharm

Inke is part of Neuraxpharm, a leading European specialty pharmaceutical company in the treatment of central nervous system disorders (CNS) and consolidated as a group in 2016. 

Neuraxpharm develops and commercializes branded and generic CNS pharmaceuticals and nutraceuticals related to the prevention of CNS indications.

Additionally, through its manufacturing companies Inke and Lesvi, Neuraxpharm has an international presence in more than 50 countries. It provides industry partners with niche active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs) across multiple technologies.

MORE

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.


© Neuraxpharm / INKE. All rights reserved.